CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Explore various ways to monetize a blog effectively. Learn strategies that can help you generate income from your writing.
7,814 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
The Amplify Seymour Cannabis ETF (CNBS) is up 105% over the past year, driven by investor bets on federal cannabis re...
As AI features roll out and iPhone upgrades loom, investors face a nuanced picture: potential stock downside from wea...
Alphabet surged over the past year, but a 10% pullback from its high has investors wondering if now is the moment to ...
Joby Aviation stock has been on a wild ride as headlines swirl around the company and the eVTOL market. This article ...
The U.S. DOJ opened the door for Paramount Skydance to acquire Warner Bros. Discovery in a $110 billion deal, signali...
Berkshire Hathaway's Greg Abel could be quietly steering a strategic tilt toward AI-enabled winners. This deep dive e...
IonQ stock recently popped in active trading, fueled by rival news and renewed optimism around quantum tech. This gui...
SMCI stock has been volatile in 2026 as AI infrastructure demand collides with a large financing plan. This piece wei...
Investors weigh SpaceX’s long-term potential as AI-driven data services and satellite connectivity could unlock a mul...
A new deal could amplify AMD's growth path by tying AI memory optimization to data-center demand. Learn why this acqu...
Kroger’s stock move today sparked questions about earnings, margins, and future guidance. This analysis breaks down w...